Repeated treatment may spare dangerous cell lineages and free them from competition
Repeated treatment could favor dangerous, death-resistant cell lineages and allow growth by removing competitors. The model would be insufficient if transferred cell-death products determine growth despite matched surviving lineages and competitors.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Specialised cell of an organ
Competing cells
Cells that limit the multiplication of other cells through competition
Where this hypothesis actsSurviving cell populations between repeated cycles of altered-cell removal
Hypotheses on this target 1
Function restoration
Reprogramming
Transplantation1
Elimination
Proliferation
What is proposed
Transplantation
Preserve or restore viable competing cells
With whatCell therapy
HowSelectively remove labelled cells while retaining competitors, or add previously characterized competitors
Possible result
Possible reduction in dangerous clones' absolute growth between cycles and stabilization of SPV_10
From the recordСохранение жизнеспособных конкурентов должно предотвращать ускорение даже при той же доле первоначально уничтоженных изменённых клеток.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Removing altered skin cells could leave the surviving population more dangerous even as visible patches disappear. The unexpected move is to preserve living neighboring cells as a restraint on dangerous survivors, rather than judge success only by how many altered cells disappear. This is a proposal generated by the pipeline, not a measured treatment result.
- Treatment preferentially spares pre-existing dangerous cell families whose resistance is linked to reduced cell death.
- The same treatment removes living neighbors that would otherwise restrain those survivors.
- Repeated differences in survival progressively increase the resistant families' share of the remaining population.
- Reduced competition lets resistant families increase their actual cell numbers between treatments.
- Preserving or restoring living competitors is predicted to prevent growth acceleration despite comparable initial cell killing.
- Maintaining that restraint is proposed to stabilize the undefined outcome SPV_10.
Repeated weeding could favor a stubborn weed if each pass also removes the plants crowding it. The bed can look clearer immediately while giving the surviving weed more room to spread.
Where the picture breaks: The picture does not establish how skin cells restrain one another or why particular cells survive treatment. Dying cells may also leave growth-promoting substances or inherited material that affects survivors, routes the picture leaves out.
- Master questionstep 01 of 04
The intended therapy would restore the functional condition of middle-aged human skin toward that of young people.
Rests on: The supplied goal explicitly names this desired outcome, but does not define which skin functions would establish it.
Stated in the chain - Goal pillarstep 02 of 04
Repeated rounds of repair may encounter limits imposed by the repair process itself.
Rests on: The goal concerns restoring skin function, but supplies no account of repeated repair or why repair would limit itself.
LeapThe connection between restoring youthful skin function and self-limitation during repeated repair is not supplied.
- Gap questionstep 03 of 04
Repeated removal of altered cells might accelerate the growth of dangerous surviving cell families despite the disappearance of visible patches. Keeping competing neighbors alive might prevent that acceleration.
Rests on: The previous stage names self-limitation during repeated repair, without identifying selective cell removal or competition as its cause.
LeapThe chain does not explain why repeated repair should be represented by removal of altered cells, or why dangerous survivors and loss of neighboring competitors are the relevant limiting process.
- Hypothesisstep 04 of 04
Repeated treatment is proposed to favor dangerous cell families already resistant to being killed while removing neighbors that constrain their multiplication. The survivors would then change in composition and grow in actual number between treatments; preserving competitors is predicted to prevent acceleration and stabilize SPV_10, an outcome identifier left undefined in the supplied material.S5
Rests on: The preceding question supplies the proposed connection between survivor growth and neighboring competitors. Cancer Surveys (1998), available here only as an abstract, describes how resistance to programmed cell death, the cell's regulated self-destruction process, can let altered skin cells survive ultraviolet exposure while normal cells die and the survivors expand. That supports a component of the proposal, but does not establish repeated therapy, growth between treatment cycles, protection from preserving competitors, or SPV_10.
Supported by literature
What is carried, and what is not. Screened sources speak to two component ideas: differential survival, as described for ultraviolet-exposed skin cells in Cancer Surveys (1998), and competition that can cause cell death, described in cultured dog kidney cells in Nature Reviews Cancer (2020). Neither establishes the proposed sequence from repeated skin treatment through loss of competitors to accelerated growth, and no supplied source establishes that sequence end to end or connects it to youthful skin function.
Where the reasoning is carried by something unstated · 2
- Goal pillar. The connection between restoring youthful skin function and self-limitation during repeated repair is not supplied. Establish the missing link before relying on this step.
- Gap question. The chain does not explain why repeated repair should be represented by removal of altered cells, or why dangerous survivors and loss of neighboring competitors are the relevant limiting process. Establish the missing link before relying on this step.
How a result here could mislead · 3
- A dangerous family's increased share immediately after treatment could be mistaken for growth, even if its actual cell count fell while other families lost more cells. What closes it: Use the proposed inherited cell labels, live imaging and absolute cell counts to separate survival immediately after removal from multiplication between cycles. Compare the immediate change in each family's share with its independently measured chance of surviving treatment.
- Slower growth after adding competitors could be attributed to competition even if the addition also changes exposure to growth-promoting substances released by dying cells. What closes it: Competitor comparisons require comparable initial killing, surviving dangerous families and exposure to products of cell death. The proposed transfer comparisons must also hold surviving families and competitors fixed while changing the transferred products; the supplied material does not specify how comparable exposure will be established.
- Failure of added neighbors to suppress growth could be read as evidence against competition when those neighbors did not survive or remain able to constrain the dangerous cells. What closes it: Verify that added competitors remain alive and present alongside the dangerous families throughout the growth interval, and establish their capacity to constrain growth. A failed addition alone cannot distinguish an ineffective intervention from a failed mechanism.
What would make this wrong. The proposed explanation would fail if verified preservation or restoration of effective living competitors did not reduce dangerous families' actual growth between cycles under comparable initial killing and exposure to products of cell death. If growth instead followed the composition of transferred products from dying cells while surviving families and competitors stayed the same, the supplied hypothesis itself states that its explanation would be insufficient.
What it would change. If the proposal held, repeated removal of altered cells could undermine a skin-restoration treatment by favoring dangerous survivors and weakening the restraint supplied by their neighbors. Work toward youthful skin function would then need to assess surviving cell families and their growth between treatments alongside the disappearance of altered patches. Even a successful test would not establish restoration of middle-aged human skin, long-term safety, or stabilization of SPV_10, whose meaning and measurement are not supplied.
Sources read · 10
Master Role of Hypoxia in Cancer Progression: Major Insights During ISOTT's Half-Century. · Advances in experimental medicine and biology · 2024
“Exposure of breast cancer cells to cytotoxic chemotherapy (e.g., carboplatin or paclitaxel) induces HIF activity leading to an increased percentage of CSCs among the surviving cells, both in vitro and in vivo ( ), which may contribute to the common recurrence of triple-negative breast cancer (TNBC) after chemotherapy ( ).”
Does not settle: The source does not establish effects of repeated treatment cycles, selection of pre-existing lineages, apoptosis suppression as the resistance mechanism, loss of competition, absolute lineage growth between cycles, maintenance of viable competitors, or stabilization of SPV_10.
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia. · Oncotarget · 2016
“The variability in the response to treatment for ALL-44 (summarized in ) indicates that there may be a stochastic element to the selection or evolution of clones with the capacity to survive drug-therapy.”
Does not settle: Источник показывает отбор или эволюцию клонов, переживающих терапию, в ксенотрансплантатах Т-клеточного острого лимфобластного лейкоза у иммунодефицитных мышей. Он не устанавливает связь устойчивости с подавлением гибели клеток, устранение конкурирующих клеток, изменение наследуемого состава популяции между циклами, увеличение абсолютной численности устойчивых линий вследствие снижения конкуренции, эффект сохранения конкурентов или стабилизацию SPV_10.
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
“Here we used liquid biopsies to identify and characterize resistance to cabazitaxel.”
Does not settle: Источник описывает устойчивость к кабазитакселу и серийный анализ плазмы у пациентов с метастатическим кастрационно-резистентным раком предстательной железы. Он не устанавливает связь устойчивости с подавлением гибели клеток, устранением конкурирующих клеток, изменением наследуемого состава популяции между циклами, абсолютным ростом устойчивых линий или стабилизацией SPV_10.
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018
“Multiple rare gene alterations driving resistance to epidermal growth factor receptor monoclonal antibodies have been described, with substantial overlap in primary and acquired mechanisms, in line with a clonal selection process.”
Does not settle: Источник не устанавливает эффекты повторной терапии, подавление гибели клеток, удаление конкурирующих клеток, рост абсолютной численности устойчивых линий между циклами или стабилизацию SPV_10.
Skin precancer. · Cancer surveys · 1998
“When a mutation confers apoptosis resistance, as TP53 mutations do, subsequent UV exposure will be more likely to kill normal cells than mutants. The latter can expand into a clone, only one cell of which need be mutated again.”
Does not settle: Источник не устанавливает эффект повторной терапии, изменения наследуемого состава выжившей популяции между циклами, абсолютный рост устойчивых линий, роль сохранённых конкурентов или стабилизацию SPV_10.
Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma. · Oncology reports · 2020
“EML4-ALK expression in HK2 cells enhanced cell colony formation and cell proliferation in vitro ( ).”
Does not settle: Источник не устанавливает эффекты повторной терапии, отбор заранее существующих линий, изменение наследуемого состава популяции, конкуренцию между линиями, их абсолютную численность между циклами или стабильность SPV_10. Защита от гибели клеток в предоставленном тексте описана только для искусственно экспрессирующих EML4-ALK клеток HK2.
FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis. · Annals of hematology · 2023
“B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.”
Does not settle: Источник не устанавливает, как повторные циклы терапии изменяют наследуемый состав выживших клонов, уменьшают ли конкуренцию, увеличивается ли абсолютная численность устойчивых линий между циклами и стабилизируется ли SPV_10.
How cell death shapes cancer. · Cell death & disease · 2015
“In this mouse model, lymphomagenesis is induced by repeated rounds of sub-lethal γ -irradiation and strongly accelerated by TP53 deficiency.”
Does not settle: Источник описывает модель лимфомы у мышей и не устанавливает последовательное изменение наследуемого состава выжившей популяции, абсолютный рост устойчивых линий между циклами, эффект сохранения конкурентов при одинаковой доле уничтоженных клеток или стабилизацию SPV_10.
Cell competition drives bronchiolization and pulmonary fibrosis. · Nature communications · 2024
“Interestingly, upon Sendai virus infection which only destroys Club cells and AT2 cells but not AT1 cells , BLCs have been shown to outcompete and replace surviving AT1 cells and bronchiolize the lung parenchymal regions devoid of AT2 stem cells .”
Does not settle: Источник не устанавливает эффект повторных циклов терапии, наследуемое изменение состава выжившей популяции, абсолютный рост устойчивых линий между циклами, связь устойчивости с подавлением гибели клеток или стабилизацию SPV_10.
Outcompeting cancer. · Nature reviews. Cancer · 2020
“Altogether, these experiments indicate that mechanical cell competition is caused by compaction-induced ROCK activation, which activates p38, leading to p53 elevation and cell death.”
Does not settle: Источник описывает клеточную конкуренцию в культурах MDCK и не устанавливает последствия повторной терапии, наследуемые изменения выжившей популяции, абсолютный рост между циклами, сохранение конкурентов при одинаковой исходной гибели изменённых клеток или стабилизацию SPV_10.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Can repeated removal leave skin clearer but accelerate dangerous surviving cells, and can preserving neighbors prevent that growth?
Original wording · exactly as the pipeline generated it
Может ли повторное удаление изменённых клеток ускорять рост опасных выживших клонов, несмотря на исчезновение очагов, и предотвращает ли этот эффект сохранение конкурирующих клеточных соседей?
What this question is asking
The question concerns whether repeatedly removing altered skin cells could allow dangerous surviving cell families to grow faster, even while visible patches of abnormal skin disappear. These cell families are called clones because their cells descend from a shared original cell. It asks whether keeping neighboring cells that compete with the survivors prevents this acceleration, compared with removal that does not preserve those neighbors. The pipeline assumes that a treatment called RL-3 clears active lesions, while competition and deeper surviving cells make that clearance an uncertain sign of lasting benefit. The intended outcome is controlled clone growth over ten years and detection of dangerous lesions before lasting damage, but the supplied material defines neither acceptable growth nor how danger is measured.
- Altered or mutant cell
- An altered cell differs from the reference cell state; a mutant cell specifically carries a genetic change. These labels do not by themselves establish that a cell is dangerous.
- Clone
- A family of cells descended from one original cell. Clone expansion means that this family increases in size or occupies more tissue.
- Lesion
- A localized patch of abnormal tissue. Its visible disappearance measures clearance of that patch, not necessarily elimination of every altered cell.
- RL-3
- The pipeline's label for the proposed skin treatment. The supplied material provides no expansion of the label or description of its components or method.
- Cell competition and competitive release
- Cell competition describes how neighboring cell populations influence which cells persist or expand. Competitive release is the proposed reduction of that restraint after competitors are removed; its occurrence after the treatment in this question remains unestablished.
- Deep surviving reserves
- The pipeline's proposed cells deeper in the skin that remain after surface lesions clear. Their location, identity and survival after treatment are not established by the supplied sources.
- Epidermis
- The outer layer of skin. The epidermis between hair follicles is the part of that layer outside the structures from which hairs grow.
- Stem cell
- A cell capable of maintaining its population while supplying cells to a tissue. Its persistence and descendants' expansion are the outcomes discussed in S2 and S4.
- Deoxyribonucleic acid
- The molecule that carries genetic information. S2 concerns cells with damage that breaks both strands of this molecule.
- p53 mutation
- A genetic change affecting p53, a protein involved in controlling cell responses to damage. The supplied findings concern particular p53-mutant cell populations and do not establish that every such mutation has the same consequences.
- Logistic growth curve
- A growth pattern in which expansion slows as the growing population approaches a limit. S6 uses this pattern to describe the approximate growth of the studied mutant clones.
- Crowding feedback and tissue homeostasis
- Crowding feedback means that local cell density changes how cells behave. Tissue homeostasis means maintaining stable tissue organization through ongoing cell activity; S6 links this stability to responses to crowding.
- Simulation
- A model that calculates how a system behaves under specified rules. S6's modeled results do not themselves establish what repeated treatment does in human skin.
- Selective growth advantage
- A relative advantage that allows one cell population to expand more successfully than others in a particular setting. It depends on context and does not itself measure damage to the organism.
- Rheumatoid arthritis synovium
- Joint-lining tissue affected by rheumatoid arthritis, an inflammatory disease. This is the tissue setting of S7, rather than skin.
RL-3 removes active lesions, but release from cellular competition and deep surviving reserves limit what visible clearance establishes about long-term risk.
RL-3 is the treatment label supplied by the pipeline, and lesions are patches of abnormal skin that it is said to remove. The assumption is that cells remaining nearby or deeper in the skin can behave differently after removal changes their surroundings. If true, disappearance of visible patches would leave unanswered whether dangerous cell families are still expanding.
S4 supports the narrower claim that spatial surroundings and cell competition influence the fate of altered skin stem cells. S6 reports a role for responses to crowding in maintaining stable tissue organization in simulations. Neither establishes that RL-3 clears lesions, that deep reserves survive it, or that repeated clearance releases dangerous survivors from competition. The supplied sources therefore support part of the ecological rationale, while leaving the treatment-specific assertions unestablished.S4S6
The same question asked without the part nothing read establishes:
- Does repeated removal of altered skin cells accelerate surviving clones despite visible lesion clearance, and does preserving competing neighbors prevent that acceleration?
- How does preserving neighboring cells change surviving clone growth after repeated removal of altered skin cells?
- Removal accelerates survivors; preserved neighbors prevent it Under the proposed mechanism, removal reduces competition and surviving dangerous clones expand faster despite visible clearance. If preserving neighbors blocks that acceleration, the cellular surroundings would determine whether clearance carries this hidden cost.
- Removal accelerates survivors; preserved neighbors do not prevent it Dangerous survivors would expand faster after removal even when neighboring competitors remain. Visible clearance and neighbor preservation would then both be insufficient to establish control of the surviving clones.
- Removal does not accelerate dangerous survivors Repeated removal would not produce the particular competitive-release effect posed by the question. That outcome alone would still not establish ten-year control or detection before lasting damage, because those are separate outcomes.
Visible lesion clearance and the subsequent growth of surviving cells are different outcomes. The proposed concern is that removing cells reduces competition, which could give dangerous survivors more room to expand; the supplied sources do not establish this sequence after repeated treatment. If that sequence occurs, clearer-looking skin could conceal worsening underlying risk. If preserved neighbors prevent the acceleration, their retention would change the consequences of removal, but their mere presence cannot be assumed to provide protection.
Полевая терапия RL-3 удаляет активные поражения; экологическое освобождение конкурентов и глубокие резервы ограничивают интерпретацию очищения.
Рост изменённых клонов остаётся в обоснованных пределах десять лет; опасные очаги выявляются до стойкого повреждения.
Не проверено, снижает ли повторное очищение долговременный риск или усиливает рост переживших лечение клонов при благоприятной картине поверхности.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Повторная терапия преимущественно сохраняет заранее существующие опасные линии, устойчивость которых связана с подавлением гибели клеток. Одновременно она удаляет клетки, ограничивающие их размножение. Наследуемый состав выжившей популяции последовательно меняется, а уменьшение конкуренции позволяет устойчивым линиям увеличивать абсолютную численность между циклами. Сохранение жизнеспособных конкурентов должно предотвращать ускорение даже при той же доле первоначально уничтоженных изменённых клеток. Поддержание такого ограничения роста должно стабилизировать SPV_10.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Теория информации: относительная энтропия Кульбака — Лейблера и условный канал выживания. Для линии i: p_i' = p_i s_i / s̄, где p_i обозначает её долю перед удалением, s_i обозначает вероятность её выживания, s̄ = Σ_j p_j s_j обозначает среднюю вероятность выживания по всем линиям j, p_i' обозначает долю непосредственно после удаления, до размножения. D_KL(p' || p) = Σ_i p_i' ln(p_i'/p_i) измеряет селективное изменение состава в натах; ln обозначает натуральный логарифм. При одинаковом s_i для всех линий D_KL = 0 даже при большой общей гибели. При повторении неизменной селекции отношение долей линий i и j умножается на (s_i/s_j)^n, где n обозначает число циклов; это выражение применимо к стадиям удаления, отдельно от межциклового роста. Связь отбора с информационными расхождениями формализована в [работе Frank](https://onlinelibrary.wiley.com/doi/10.1111/jeb.12010). Перенос касается селективной потери клеток, а не клеточного распознавания или передачи позиционных сигналов.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Измеренные до опыта вероятности выживания каждой линии должны предсказывать её обогащение сразу после каждого удаления. При одинаковой общей гибели режим, сильнее сохраняющий опасные линии, даст большее их обогащение. После этого сохранение либо восстановление живых конкурентов должно уменьшить абсолютный межцикловой прирост опасных линий при сопоставимых продуктах гибели. Для объяснения результата не потребуются новые донорские последовательности. Если рост определяется составом перенесённых продуктов гибели при одинаковых выживших линиях и конкурентах, данная модель будет недостаточной.
Would tell it apart from at least one rival. The prediction specifies directional comparisons under comparable conditions and an explicit condition for model insufficiency. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Клональные метки, прижизненная микроскопия и абсолютный подсчёт клеток позволяют раздельно оценивать гибель и последующее размножение. Селективное удаление маркированных клеток и добавление заранее охарактеризованных конкурентов позволяют изменять состав популяции независимо от количества продуктов гибели.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Измеренные до опыта вероятности выживания каждой линии должны предсказывать её обогащение сразу после каждого удаления. При одинаковой общей гибели режим, сильнее сохраняющий опасные линии, даст большее их обогащение. После этого сохранение либо восстановление живых конкурентов должно уменьшить абсолютный межцикловой прирост опасных линий при сопоставимых продуктах гибели. Для объяснения результата не потребуются новые донорские последовательности. Если рост определяется составом перенесённых продуктов гибели при одинаковых выживших линиях и конкурентах, данная модель будет недостаточной.
- Rival 01 of 02Repeated skin cell killing may speed growth by combining inherited DNA from dead clones
Not yet published.
What would separate themRepeated skin cell killing may speed growth by combining inherited DNA from dead clones predicts: В мозаичной модели кожи погибающие клоны получают разные нейтральные генетические метки рядом с исследуемыми аллелями, а реципиенты имеют независимую метку происхождения. После повторных циклов ускоренно растущие потомки реципиентов должны содержать устойчиво наследуемые донорские фрагменты с подтверждёнными местами интеграции. Удаление ДНК из выделенной фракции продуктов гибели должно устранять ускорение при сохранении её липидного состава; возвращение интактного материала должно восстанавливать эффект. Отсутствие интеграции при достаточной чувствительности и сохранение ускорения после удаления донорской ДНК опровергнут гипотезу в пользу отбора либо растворимого ростового стимула.
- What would separate them
Signals from dying cells may drive altered skin cell growth through prostaglandin E2 predicts: При одинаковых выживших линиях, количестве конкурентов и исходной гибели перенос бесклеточной среды, освобождённой от ДНК и клеточных частиц, должен воспроизводить ускорение роста. Подавление образования простагландина E2 в погибающих клетках должно устранять эффект, а возвращение измеренной концентрации медиатора должно его восстанавливать. После прекращения таких импульсов дополнительная скорость роста должна снижаться. Устойчивое ускорение после длительного удаления медиатора, особенно связанное с новым наследуемым генотипом, будет аргументом против этой гипотезы.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.